Clade Therapeutics, which is developing off-the-shelf cell therapies, has dismissed a number of staffers in the US and Europe, according to social media posts made by employees and a top executive at the company.
“Yesterday, at Clade we went through the painful process of a ‘reduction in force’ and parted ways with many of our valuable colleagues,” chief business officer and co-founder Jim Glasheen wrote in his LinkedIn post several days ago.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.